Krakow, Poland

NZOZ Centrum Medyczne Promimed

Ulcerative Colitis

Rheumatoid Arthritis

Arthritis

Colitis

Ulcer

ABX464

Etrolizumab

ASP015K

Adalimumab

Methotrexate

Filgotinib

ABIVAX

Roche

Alfasigma

Astellas

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\].

This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.

ABTECT - Maintenance

NZOZ Centrum Medyczne Promimed | Krakow, Poland

Site insights

Work at this site?

Active trials

ABTECT - Maintenance

Trial sponsors